San Diego-Area Biotechs Dominate “Startups to Watch” List

Home/Financial/San Diego-Area Biotechs Dominate “Startups to Watch” List

San Diego-Area Biotechs Dominate “Startups to Watch” List

From Biospace:

“BioSpace (DHX) is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States. Once BioSpace sorted the companies into that group, they were then weighted by a number of different categories and ranked in a cumulative fashion based on the points awarded for each category. These categories are: Finance, Collaborations, Pipeline, Sales and Editorial (view methodology).

The NextGen Bio Class of 2016 is a stellar group of companies that are already making an enormous impact on the industry now and in the future. Congratulations!

California led the way in the NextGen Bio “Class of 2016” with half of the companies in the Top 20, followed by Massachusetts with five, and one company each in New Jersey, Texas, New York, Washington and North Carolina.”

San Diego-area Companies on List:

12. Adrenergics
Points: 5
Founded: 2014
Location: La Jolla, Calif.
Notable:
• Adrenergics is developing novel therapeutics to treat dilated cardiomyopathy (DCM) in patients who do not respond to existing therapies. DCM is a disease of the muscle of the heart, which usually starts in the left ventricle—the chamber of the heart responsible for pumping activity. Thinning of the left ventricle causes it to not pump blood effectively, resulting in inefficient blood supply throughout the body.
• Adrenergics was launched as one of several collaborations between Avalon Ventures and GlaxoSmithKline (GSK) with $10 million from a Series A financing round, and research and development support from Avalon and GSK. It is located at COI Pharmaceuticals in San Diego, which is a community of innovation founded by Avalon to provide operational support, a fully equipped R&D facility and an experienced leadership team.

14. CadheRx
Points: 5
Founded: 2014
Location: La Jolla, Calif.
Notable:
• Launched as one of several collaborations between Avalon Ventures and GlaxoSmithKline, CadheRx received $10 million in a Series A financing round and R&D support from Avalon and GSK. It is located at COI Pharmaceuticals in San Diego, a community of innovation founded by Avalon.
• CadheRx is developing therapeutic antibodies targeting soluble E-cadherin (sEcad) for the treatment of solid tumors that are resistant to other treatments, particularly Cetuximab and Herceptin-resistant epithelial cancers. sEcad levels are increased in many epithelial cancers and result in increased tumor cell proliferation, migration, invasion and angiogenesis.
• CadheRx was founded on intellectual property in-licensed from the laboratory of Sabine Brouxhon, MD, clinical associate professor, Department of Emergency Medicine in the School of Medicine at Stony Brook University.

15. Calporta
Points: 5
Founded: 2014
Location: La Jolla, Calif.
Notable:
• Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases.
• Calporta’s approach is based on research from the lab of Haoxing Xu at the University of Michigan.
• Calporta launched as one of several collaborations between Avalon Ventures and GlaxoSmithKline. It received $10 million in a Series A financing round and R&D support from Avalon and GSK. It is located at COI Pharmaceuticals in San Diego, a community of innovation founded by Avalon. GSK has the option to acquire the company upon the identification of a clinical candidate. Should GSK elect not to exercise its option on any of the companies, ownership of those companies will remain with Avalon, and Avalon will be free to enter into other strategic transactions.

16. Silarus Therapeutics
Points: 5
Founded: 2014
Location: La Jolla, Calif.
Notable:
• Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders, such as anemia. Erythroferrone is a recently discovered hormone that regulates the iron supply for red blood cell production.
• Silarus was founded based on intellectual property in-licensed from the University of California, Los Angeles, that was discovered by investigators Tomas Ganz, professor of Medicine, Department of Pathology and Laboratory Medicine andElizabeta Nemeth, professor of Medicine, Division of Pulmonary and Critical Care, both of the UCLA David Geffen School of Medicine.
• Launched as one of several collaborations between Avalon Ventures and GlaxoSmithKline, Silarus received $10 million in a Series A financing round and R&D support from Avalon and GSK. It is located at COI Pharmaceuticals in San Diego, a community of innovation founded by Avalon.

17. Thyritope Biosciences
Points: 5
Founded: 2014
Location: La Jolla, Calif.
Notable:
• Thyritope Biosciences is focused on drugs that target thyroid stimulating auto-antibodies, which are linked to Graves’ hyperthyroidism and Graves’ orbitopathy. Graves’ disease is an autoimmune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. There is currently no approved treatment for Graves’ orbitopathy.
• Thyritope was founded based on molecular evolution technology developed by Patrick Daugherty, professor of Chemical Engineering, and Biomolecular Science and Engineering at the University of California, Santa Barbara and commercialized by Serimmune.
• Thyritope was launched as one of several collaborations between Avalon Ventures and GSK. Thyritope received $10 million in a Series A financing round and R&D support from Avalon and GlaxoSmithKline. It is located at COI Pharmaceuticals in San Diego, a community of innovation founded by Avalon.

19. Metacrine
Points: 4
Founded: 2015
Location: San Diego, Calif.
Notable:
• Metacrine is privately held and based on technology licensed from the laboratory of Ronald Evans of the Howard Hughes Medical Institute at the Salk Institute. The company plans to leverage two mechanistically distinct programs to target diabetes, steatohepatitis, and other metabolic and liver disorders.
• In August 2015, Metacrine raised $36M in a Series A financing. Participants included Arch Venture Partners, EcoR1 Capital, Polaris Partners and venBio.

 

FULL LIST and INFORMATION

January 26th, 2016|
X